If the proposed pathophysiology involving the IL-17/IL-23 signaling pathway holds true for uveitis and certain cardiovascular comorbidities, it raises intriguing questions about the potential therapeutic implications of targeting the IL-17/IL-23 axis. The gene discussed is IL17A; the disease is uveitis.